Author Archives: Danzig

Democratic lawmakers introduce a resolution to amend the 13th Amendment to end forced prison labor – KNBR

Posted on by

Congressional Democrats want to amend a section of the 13th Amendment, which abolished slavery, to end what they refer to as another form of slavery forced prison labor.

Sen. Jeff Merkley of Oregon and Rep. William Lacy Clay of Missouri introduced a joint resolution this week that would remove the 13th Amendments punishment clause, or language that excepted convicted prisoners from the ban on slavery and involuntary servitude.

Our Abolition Amendment seeks to finish the job that President Lincoln started by ending the punishment clause in the 13th Amendment to eliminate the dehumanizing and discriminatory forced labor of prisoners for profit that has been used to drive the over-incarceration of African Americans since the end of the Civil War, Clay said in a statement.

When it was ratified in 1865, the 13th Amendment made slavery illegal except as punishment for a crime of which one has been convicted, the amendments text reads.

The Abolition Amendment would strike that clause from the 13th Amendment and end forced labor among prisoners, the congressmen said. Work programs for prisoners would continue on a voluntary basis.

Avi Soifer, a professor and former Dean of the University of Hawaii at Manoas Richardson School of Law, told CNN that its unlikely that efforts to amend the constitutional amendment will succeed.

It may be more beneficial to institute partial remedies, he said, like the federal statute that outlaws voluntary and involuntary peonage, a type of servitude by which people who owe debts work until those debts are paid.

It thus could have immediate relevance in efforts to address the terrible ways that we now treat prisoners and those jailed because they are unable to make bail, said Soifer, a 13th Amendment expert.

Merkley and Clay, in their release, call the punishment clause in the 13th Amendment indisputably racist in origin and in impact.

Because the South relied on slave labor for its economy in the 19th century, that line in the amendment was used as a loophole to continue the forced labor of Black Americans who were imprisoned, according to the non-profit Equal Justice Initiative, which works to end mass incarceration.

The punishment clause led to higher rates of arrests among Black Americans throughout the Jim Crow era to the War on Drugs in the 1980s, the congressmen said in the release, by effectively creating a financial incentive for mass incarceration renting forced labor of disproportionately Black prisoners.

Prison labor is a lucrative industry. NPR reported in July that as of the last federal count in 2005, over 1.5 million prisoners were working. UNICOR, a federal prison labor program, generates over $500 million in revenue every year, NPR reported.

But the practice exploits prison laborers, its opponents say. Many states, mostly in the South, dont pay inmates for working regular prison jobs, according to the Prison Policy institute, and the high end of their wages for regular prison jobs rarely exceed $1.

Sens. Bernie Sanders and Ed Markey, among others, have cosponsored the amendment, which has earned the support of social justice organizations like Human Rights Watch, Amnesty International and Color of Change.

Continued here:

Democratic lawmakers introduce a resolution to amend the 13th Amendment to end forced prison labor - KNBR

U.S. Tech Giants Face Tighter Regulation in Europe – The Wall Street Journal

Posted on by

The European Union plans to introduce in coming weeks new proposals aimed at changing behaviorand, in some cases, business modelsat large online platforms, reasserting the blocs role as global tech cop.

The European Commission, the blocs executive arm, is completing regulatory plans outlining how online platforms should remove illegal content quickly and refrain from using their power to quash rivals or push their own products on their sites. The commission plans sanctions for violators that include fines and possible separation of assets, according to people familiar with the matter.

Under the plans, the bigger and more influential a companybased on criteria including market share and revenuethe more obligations it will shoulder. The rules, though not targeting any specific company, are likely to apply to U.S. tech companies including Alphabet Inc.s Google, Facebook Inc. and Amazon.com Inc., according to EU officials.

In response to the coming regulations, tech companies and industry groups have warned against creating a new set of competition rules that could hobble innovation.

Were at risk of limiting entire ecosystems because of concerns that a handful of U.S. companies have gotten too big, said Kayvan Hazemi-Jebelli, competition and regulatory counsel for the Computer & Communications Industry Association, a lobbying group that represents companies including Amazon , Facebook and Google.

More here:

U.S. Tech Giants Face Tighter Regulation in Europe - The Wall Street Journal

Breaking up the tech giants won’t be enough to rein in their power – Open Democracy

Posted on by

Hardly any tech giant is spared an antitrust investigation these days. In the United States, Google is facing the biggest antitrust case in a generation. Across the Atlantic, the European Commission has brought formal antitrust charges against Amazon. In the UK, the Parliament has launched an enquiry into music streaming by platforms such as Spotify, Apple Music, Amazon Music and Google Play.

This was overdue. A decade of light to no regulation enabled a historical consolidation of platform wealth and power. The COVID-19 pandemic has made it painfully obvious how much we depend on digital platforms and how our lives are entangled with them. Crucial platform products and services like health technology (Google and Apple), food and groceries delivery (Deliveroo), transport (Uber) and the supply of essential goods (Amazon) underline to what extent they have become indispensable intermediaries of everyday life. Tech regulation is coming, and we need changes that thoroughly democratise their governance and challenge concentrated corporate ownership.

Breaking up platforms is a popular proposal for antitrust action. But this might not be enough to tackle the true source of platforms monopolistic power. Breaking up Facebook (Facebook, Instagram, WhatsApp) or Alphabet (Google, Youtube, Nest) wont profoundly change their dominant position in their respective markets. Facebook and Google are dominant because they have built network effects. The value users derive from using the platform increases with the number of other users. Owning and operating the digital structure through which these users interact allows platforms to extract valuable data and charge for access to the platform (e.g. in form of subscription or commission fees). This essentially makes platforms the big rentiers of our time, receiving revenue flows from the digital space they enclose.

As long as platforms were perceived to add value and drive innovation they evaded widespread criticism. But this narrative has broken down and concerns about platforms abusing their intermediary power are mounting. The antitrust case against Alphabet focuses on Google harming competition by paying other companies to set its search engine as the default option. Amazon is being sued over using retail data they extracted from their marketplace to boost their own products and compete with sellers. Meanwhile a market study conducted by the Competition and Markets Authority (CMA) showed concern about Facebook and Googles role in stifling innovation and using their market power to raise the price of digital advertising.

The prevalent tech-solutionist discourse makes platform dominance sound inevitable, integral to our contemporary configuration technology and society. But there are alternatives. The challenge is to liberate the democratic potential of the platform from the logics of concentrated corporate ownership and profit maximisation. Crucially, while platforms have encouraged a sense of technological inevitability, the way that our digital economy is run is neither fixed nor certain. Platforms are legal as much as digital institutions; we can recode both and change how they operate and in whose interests. We can disperse and democratise economic coordination rights currently monopolised by the platforms, ensuring private power is not beyond democratic regulation. Central to this must be a new architecture of ownership and control.

Excerpt from:

Breaking up the tech giants won't be enough to rein in their power - Open Democracy

Why we should rein in the big tech giants in 2021 and beyond – The Conversation US

Posted on by

The COVID-19 pandemic has made it clearer than ever that we are at risk of losing control of our economies.

Our institutions have increasingly struggled to meet the challenges of economic development before the crisis, and yet throughout the pandemic weve seen surging stock market valuations of tech giants including staggering CEO salaries the inability of anti-trust regulators, particularly in the United States, to effectively regulate markets and the rise of Chinas tech companies.

Tech giants are not just surviving the pandemic; theyre thriving.

Whats known as the superstar economy is one with a few hyper-productive, gigantic and highly profitable companies.

Superstar firms such as Walmart, Amazon or Facebook use new technologies to redefine markets, and benefit from what are known as network effects simply put, the value of a product is enhanced the more people use it. Facebook is an example people are more likely to join Facebook if their friends and loved ones are on it.

Initially, superstar companies bring new ways of delivering value to customers, but as they grow, they become powerful monopolies. Our institutions have struggled with how to deal with these relatively new firms and, for example, have allowed many mergers and acquisitions that eroded competition in their respective markets. Prominent examples include the acquisition of Instagram and WhatsApp by Facebook.

Superstar firms have also contributed to the shift in wealth distribution from labour to capital. Wealth was once commonly built through labour, rather than via capital that is often inherited or otherwise privileged.

Many superstar firms also have the balance sheets of mid-sized economies and hold more information about us than any country. Take Facebook. Mark Zuckerberg probably knows more about you than your government. However, you have no way of finding out because data ownership is at best a complicated issue, and retaining your data would require you to have next to no online footprint.

That citizens dont have access to data about themselves is problematic. Clearly, the only person who should own your data is you. European data privacy laws are about to become even stricter, but in North America, the erosion began in the aftermath of the Sept. 11, 2001, terrorist attacks that resulted in laws that dramatically eroded our privacy. Those laws have provided firms with the right to use the abundant data they collect.

Google is an example. One of the reasons Google is the gold standard of search engines is that it uses advanced machine learning algorithms. These algorithms use our data to learn what we want to see when were online.

Any successful competitor to Google would need to outperform years of learning advantage. That makes competition at best very challenging.

Primarily, we have seen two attempts to address the sheer might of tech giants and their lack of competitors.

In China, superstar firms have been largely nationalized. The state is increasingly involved in the most powerful companies in the country. Chinese regulators recently quashed the initial public offering of a financial company, Ant Group, in a high-profile example of government involvement.

Read more: Ant Group is holding the biggest IPO of all time here's what it is

In such a regime, the state is set up to have unlimited access to your data, so the principles upon which western democracies were built do not apply.

Second, in the western world, we traditionally address issues of market domination with antitrust regulations. Antitrust laws have started to hit the superstar economy hard in Europe. Google alone had to pay fines of US$9.3 billion in the last three years.

However, antitrust measures have so far not been very effective given theres little room for action its either none at all or breaking up companies, which authorities are often hesitant to do.

Examples of such limited success from the past are Standard Oil and, later, AT&T. Standard Oil served America as a monopoly before it was broken up into 34 smaller companies in 1911. Many of these companies are known today under the names Chevron, ExxonMobil, BP and Marathon. Decades later, AT&T was also broken apart into seven smaller, regional companies.

The west also seems ill-equipped to regulate new markets that have emerged outside the traditional boundaries of an industry, including the highly digitized sectors that were fuelled by the growth of the internet over the past few decades.

Antitrust regulations for tech companies in the post-pandemic era need to change. Restricting networked companies to expand beyond their core business, and preventing mergers and acquisitions that inhibit the self-regulating character of markets, could increase the competitive forces in the market.

For example, Amazon as a platform for connecting buyers and sellers has transformed how we buy things. However, there is an obvious conflict of interest and a threat to competition when Amazon offers their own products on their own platform. Microsoft, as a provider of the most popular operating system for computers in the world, is a threat to competitors by offering its own browser.

There is no harm in restricting superstar firms to their core businesses, but a lot of harm when we dont.

Regulators need to better understand the innovative forces in industries and markets to prevent anti-competitive behaviour rather than looking at traditional measures like market share. More competitive markets would offer better outcomes for consumers.

Better antitrust measures also require applying national data security laws. In practice, this would mean that all online platforms need to fulfil the national regulations in the markets where theyre doing business as opposed to only in their home countries. These ideas are currently being advanced in Europe and will likely be a game-changer for tech giants.

A localized market approach could also reduce the effect of data breaches. Competition would become healthier as well, because superstar firms couldnt impose the rules of the game in the same way anymore.

We must better define the role of superstars in our economies and decide whether its wise to readjust our market principles to accommodate tech giants, or whether we should restrict tech giants to adhere to our market principles.

Capital-rich investors will certainly enjoy reaping the benefits from accommodating the Googles and Amazons of the world but the average customer likely wont.

See the original post here:

Why we should rein in the big tech giants in 2021 and beyond - The Conversation US

Tech Giants of Silicon Valley: Friend or Foe to the Fitness Industry? – Club Industry

Posted on by

The Digital Age has been upon us for a while, and yet, as an industry we have been slow adopters, dipping the toe in the water with technology rather than being bold and diving in. The pandemic has been the catalyst that has forced the worlds fitness industry to embrace the possibilities on offer and adjust to meet the needs of the consumer. However, the increased consumer engagement with digital fitness, accelerated by global lockdown restrictions, has also awoken the sleeping giants of Silicon Valley.

As an industry, we have been caught on the back foot by tech giants such as Apple, Facebook, Mirror and Tonal who have been alerted to the consumers appetite for home fitness and fitness tech, recognizing the commercial opportunity, and have launched their own tech-driven fitness services and products. With bigger budgets, seemingly endless resources, established brand loyalty and a global audience, these newcomers to the fitness space have placed a huge amount of pressure on our industry, forcing us to expand digital offerings, enhance quality and meet customer demand in a fast-changing marketplace.

The biggest brands in technology, now with their sights firmly set on the fitness industry, will take no prisoners. How can club operators fight back in a David and Goliath style battle to win over consumers and secure their industry place for the future?

Anything that gets the population moving is a good thing. Getting more people more active more often is the whole reason we all work in the fitness industry. We all have a passion and drive to improve peoples physical and mental well-being through activity. So any new solution that promotes this is positive.

The focus that big players have placed on the fitness industry drives more investment, awareness and interest in exercise, creating a much bigger potential net of customers. As they say, a rising tide lifts all boats. It is also the case that as digital solutions help more people work out from home, confidence and ability increases, and these people may soon seek a facility or club as their next step.

More people engaging in activity is a good thing. The data that digital brings also allows companies to analyze at a whole new level, adjusting offerings to meet real-time engagement. But as a business in the fitness industry, recent moves by these companies have the potential to steal customers from facilities, tempting them with more accessible and affordable digital offers. They can rapidly develop new technology and new high-quality content, and they have the ability to stifle any creative moves the fitness industry makes to open new revenue streams through digital delivery.

An argument exists that some of these companies, including Apple and Google, are operating with a conflict of interest, as they can self-promote their own product, hold data from devices pushing their own product and operate in a developer-locked environment.

Health club operators offer fitness experiences, not just a workout. In-club activity offers a social aspect that cant be replicated through virtual experiences, and the four walls of a facility act as a cathartic change of scene, a space away from both work and home.

Many clubs also offer a range of activities, including spas, work-spaces, cafes and restaurants, sport facilities and child-care, as well as the unrivaled access to experienced professionals and support and a wide range of equipment options that cannot be matched by at-home gyms.

Digital fitness often offers no personal accountability, individual goal setting or performance reviews. This brings a risk of injury or a lack of professional support with no one focused on the assessment of technique. The nature of the digital fitness scene also highlights trainers with perfect bodies, the fitness ideal, but this is an unrelatable and unrealistic representation, especially to those new to fitness, which many of the home-fitness users are, and can have a negative impact on mental health, self-confidence and self-esteem.

In the United Kingdom, we know that roughly 16 percent of people participate in gym or fitness classes at least on a monthly basis. But these tech giants will attract to fitness a whole new consumer group, reaching a greater percentage of the population, not just in the United Kingdom but globally. Yes, this will grow the interest in fitness and in turn, the industry butand this is a big butunless we can compete we wont get a slice of this pie. When Silicon Valley does something, it does it well. The quality of this product will not be substandard, and we need to up our game with quality content and member engagement in order to remain in the game.One thing the fitness industry does have to its advantage is community. Despite the exciting appeal of some of these new developments, there is still something to be said for working out with people from your local area, socializing with them as a community, training with your trainer who knows you and your goals, and having loyalty for your local gym chain. No one wants to be a faceless number at the back of a digital class when they can be seen and heard, surrounded by a supportive community of people they know.

Digital is here to stay. But there is still a demand for the personable experience that in-club activity can deliverreal people delivering real experiences. Therefore, the hybrid model, a wrap-around combination of both in-club and digital on-demand offerings, is the perfect solution to meet consumer demands, providing personalization, accountability and connection to others while allowing the user the ability to select when and where they train.

Digital cannot replicate the in-person experience and community creation that drives a sense of belonging and the feeling that we are in this together or the face-to-face access to professional support. But digital options can supplement the in-club experience and help consumers integrate their fitness journey into their lifestyle, giving them the ability to train anywhere, anytime.

To date, Silicon Valley does not have the assets to deliver the in-person experience. As long as our sector has brick-and-mortar facilities, thisand the communities we create around themremain our standout unique selling proposition.

There is a lot of talk in the United Kingdom about the missed opportunity of our sector to be considered by government as essential to a preventive health care strategy. Currently, gyms are classified with pubs and cinemas. To protect our market position, we need to think much wider than the fitness outcomes we deliver and focus more on the wider health outcomes. We need to talk more about protection against infection and disease and prevention against long-term health issues such as diabetes, heart disease and some forms of cancer. Our language needs to shift from COVID secure to regulated.

If we shift into the health space and start to link our services more to government prevention rather than cure health care strategies, we create an opportunity to serve a much bigger segment of the population. Most people seeking health outcomes from exercise are likely to be deconditioned non-exercisers who need help and support from professionals to be able to train smart and safely toward personal health outcomes. This will require an in-person service. This is where the opportunity lies for our sector. Let the tech giants support the fit-natics and the health conscious who want to track and monitor health indicators; we will deliver the in-person exercise prescription. I honestly cant see our GP service ever moving online because people need and want a face-to-face consultation. Yes, digital services can enhance and support this, but I dont ever see the personal in-person consultation vanishing from our health care system. This should be the same in the prescription of physical activity plans for a healthy, fulfilling life.

The sector now needs to re-evaluate our market position and ambition for the future. We need to unite via our trade associationsIHRSA, Europeactive, UKactive. The case for change is well established. The positive impact of regular activity on health has been proven time and time again. We dont need any more evidence to support the case for change. What we do need is a joined-up strategy to drive the charge.

Digital will undoubtedly play a part in this, but the ability of brick-and-mortar clubs to deliver an outstanding in-person physical experience remains our biggest selling point. Tech giants from Silicon Valley cant compete with us on this. In fact, we should be collaborating with them rather than competing with them. Their health monitoring and tracking technology will be useful as we move into the health space. If we try to compete with them like for like, we will struggle. Instead, we need to create our own niche in the market.

We must focus on the delivery of an outstanding in-club experience, a unique selling point that Silicon Valley cannot yet match, supported by a quality digital provision. The two together will create a future-proof, closed ecosystem, enabling club operators to become an integral partner in a persons health and fitness journey.

If you would like to discuss the introduction or enhancement of your digital offer, visit http://www.fisikal.com or email: [emailprotected].

BIO

Rob Lander, CEO of Fisikal, has more than 20 years of experience in the health and fitness industry, as a former personal trainer who built a successful business of 50 sessions per week. Lander has also spent many years as an international presenter lecturing on technology in the fitness industry. He started with little knowledge of technology other than the vision that one day we would all be using it for many areas of our lives. Organizations all over the world now come to Fisikal seeking our advice on how systems and processes can be optimized. Landers experience working in all areas of the fitness industry gives him multiple perspectives to help advise on how solutions can be created. His advanced knowledge of technology also gives him insights into what the future holds and how we can adapt internal processes so they can leverage technology efficiently.

Continue reading here:

Tech Giants of Silicon Valley: Friend or Foe to the Fitness Industry? - Club Industry

Tech Giants Threaten to Pull Out of Pakistan Over New Rules on Blocking Content Free Press of Jacksonville – Jacksonville Free Press

Posted on by

Islamabad, Pakistan Tech giants Google, Facebook and Twitter have threatened to withdraw from Pakistan after the government issued new rules that give it more authority to control online content.

The government on Nov. 20 officially issued the Removal and Blocking of Unlawful Online Content (Procedure, Oversight and Safeguards) Rules 2020, which grant the Pakistan Telecommunications Authority (PTA) the power to remove or block access to unlawful online content through any information system.

The rules apply not only to social media platforms, but also to all internet service providers (ISPs). Social media companies and ISPs are now required to provide any information or data in decrypted, readable and comprehensible format if an investigation agency demands it.

The Asia Internet Coalition, an industry association whose members include Google, Facebook, Twitter and other global tech giants, released an extremely critical statement on Nov. 19 expressing its members alarm at the scope of the new law.

The draconian data localization requirements will damage the ability of people to access a free and open internet and shut Pakistans digital economy off from the rest of the world. Its chilling to see the PTAs powers expanded, allowing them to force social media companies to violate established human rights norms on privacy and freedom of expression, the statement reads.

Under the new rules, social media platforms with more than a half-million users in Pakistan must register with the PTA within nine months. A PTA spokesperson could not be reached for comment.

The rules state that ISPs and social media companies can be fined PKR 500 million ($3 million) for violating the new directives. ISPs and social media companies must also restrict hate speech, content inciting violence, pornography, terrorism and threats to national security.

The law states that the blocking of access to online content would be necessary in the interest of glory of Islam; integrity, security and defense of Pakistan; public order; and decency and morality.

The rules indicate that in the near future Pakistan may promulgate a Data Protection Law, making it obligatory for ISPs and social media companies to have their database servers in Pakistan.

The rules also state that once the government reports an issue, the ISPs and social media companies must block access to unlawful content within six hours in case of emergency, otherwise within 24 hours.

Farieha Aziz, co-founder of Bolo Bhi, an organization that promotes digital rights, said that if AIC members withdraw from Pakistan, it would have a severe effect on the countrys economy.

There are so many users earning their livelihoods from social platforms such as TikTok or YouTube, she said. If these companies decide to withdraw from Pakistan or are stopped from providing services what will happen to these users?

Pakistan banned the popular Chinese app TikTok on Oct. 9 for allegedly sharing indecent content. China is an ally of Pakistan, and the ban was lifted later in the month after Tik Tok agreed to remove vulgar content.

We suspect that these rules may create resistance and a conflict-type situation between the government and billion-dollar social media companies, said Asad Baig, founder ofMedia Matters for Democracy, a Pakistan-based nonprofit that promotes freedom of expression.

We are living in a global world, where if billion-dollar companies are doing business in your country, they also create an eco-system where local people also earn. What our policymakers are failing to understand is that we should be working with these companies to take advantage of their investments and services instead of making them accountable, she said. The companies would not be on the receiving end as Pakistan is a small fish and these companies have the whole world to do business with.

The AIC said the government had promised consultation on the new rules, but that never happened.

Prime Minister Imran Khans government faced severe criticism inside and outside of Pakistan after publishing the first draft of the rules in February.

The prime minister then initiated the consultative committee. There is a complete lack of transparency, Aziz told Zenger News. The power and the mandate of the committee were not to formulate rules but to give guidelines to the PTA to formulate rules. But here the committee itself has formulated rules.

What our policymakers are failing to understand is that we should be working with these companies to take advantage of their investments and services instead of making them accountable, she said. The companies would not be on the receiving end as Pakistan is a small fish and these companies have the whole world to do business with.

Pakistan was classified not free in the Freedom on the Net 2020 report of Freedom House, a U.S. government-funded nonprofit.

The online environment in Pakistan is tightly controlled by the government. Internet shutdowns, blocked websites, and arrests for activity online remain authorities preferred tactics in their effort to suppress unwanted speech, Freedom House said in its report.

(Edited by Siddharthya Roy and Judith Isacoff)

Read more here:

Tech Giants Threaten to Pull Out of Pakistan Over New Rules on Blocking Content Free Press of Jacksonville - Jacksonville Free Press

Tech Giants Face a Tough New Regulator in the U.K. Heres Why it Matters. – Barron’s

Posted on by

Text size

Tech companies operating in the U.K. will face a new, specialized regulator that is expected to introduce rules around user data and consumer choice. It is set to curb the market power of companies including Google, owned by Alphabet (ticker: GOOGL), and Facebook (FB).

The move from the British government comes as tech giants face new challenges in the European Union within weeks, when draft proposals for legislation governing digital markets come on Dec. 9.

The back story. In July, Britains Competition and Markets Authority released the results of a year-long study into online platforms and the digital advertising market in the U.K. The study specifically investigated the market power of Google and Facebook, describing how the companies overwhelmingly dominate in online search, social media, and advertising, and enjoy incumbency advantages that protect them against rivals and reduce competition.

In March, the CMA was asked to lead a Digital Markets Taskforce to advise the government on the design of a new regulatory regime for digital markets. That task force is due to provide its proposals before the end of the year.

Whats new. The British government announced on Friday that it would set up a Digital Markets Unit within the CMA to oversee pro-competition reforms in the tech sector. The new unit will begin operating in April 2021.

Digital platforms like Google and Facebook make a significant contribution to our economy and play a massive role in our day-to-day lives, said Alok Sharma, Britains business secretary. But the dominance of just a few big tech companies is leading to less innovation, higher advertising prices and less choice and control for consumers.

Also read: Big Tech And Antitrust: Where Things Stand

The regulator will establish rules to govern platforms funded by digital advertising that have strategic market statusthe designation of which is another task of the new body. Its mandate includes introducing pro-competition interventions around user data, consumer choice, and could extend to breaking up businesses.

Andrea Coscelli, the CMAs chief executive, said that only through a new pro-competition regulatory regime can we tackle the market power of tech giants like Facebook and Google and ensure that businesses and consumers are protected.

Plus: Google Promises the EU It Wont Use Fitbit Health Data to Target Ads

Looking ahead. Make no mistake: the creation of a new tech regulator with a mandate to target companies like Google and Facebook is trouble for big tech. It comes as these same companies are already facing down the barrel of strict regulation across the English Channel making Europe stand out as a trouble spot.

Its difficult to tell how deep new intervention will run. The CMAs chief executive has been aggressive in calling out Google and Facebook, but the U.K.s business secretary was right to note the significant contribution these companies make to the British economy. Regulation like this could very well become a major political issue.

Email: editors@barrons.com

Read the original post:

Tech Giants Face a Tough New Regulator in the U.K. Heres Why it Matters. - Barron's

Apple isn’t joining French initiative to push tech giants to pay more tax – Cult of Mac

Posted on by

Apple has reportedly declined to sign on to a new French initiative that asks big tech companies to commit to paying their fair share of tax.

French President Emmanuel Macron has set up a Tech for Good Call that will seek to implement these changes. However, while Google, Microsoft, Facebook and 72 other companies have joined, Apple and Amazon havent signed on yet.

According to Reuters:

Apple declined to comment, but French officials said talks with the group were ongoing and they could still join the initiative, details of which will be published officially by Tuesday. A representative for Amazon, which French officials said had declined to join the initiative, did not return a request for comment.

The French initiative is not legally binding. Nonetheless, Macron is taking it very seriously. He plans to use it to influence future negotiations when it comes to the regulation of big tech.

Tech for Good Call isnt only about taxes. In addition to asking for a commitment to contribute fairly to the taxes in countries where [tech giants] operate, it also covers other areas. These include stopping the spread of child sexual abuse material, terrorist or extreme violence online contents and supporting new sustainable initiatives.

At this point, it remains clear why Apple did not back the initiative. Apple CEO Tim Cook previously called for a global overhaul of corporate taxes. But he also consistently insists that Apple pays its fair share.

During a 2015 Inside Apple episode of60 Minutes, Cook dismissed reports that Apple doesnt pay its way as total political crap. In an interview this year, he said that Applesresponsibility is to pay what we owe. Beyond this, Cook notes how Apple contributes through donations and initiatives like its COVID-19 crisis response.

My own view is that you pay what you owe in taxes, and then you give back to society, he said.

However, there is some precedent for believing that Apple doesnt pay the full amount it should. In 2019,Apple agreed to pay French authorities around $571 million in back taxes. (With that said, a separate, much larger EU tax bill was overruled in Apples favor earlier this year.)

Source: Reuters

Original post:

Apple isn't joining French initiative to push tech giants to pay more tax - Cult of Mac

Tech giants to be subject to a new code of conduct – Lexology

Posted on by

The Government has announced that it will establish a new regime designed to govern the behaviours of the tech giants. It plans to set up a Digital Markets Unit, operating within the Competition and Markets Authority (CMA), which will introduce and enforce a new statutory code of conduct. The Government has indicated that, among other things, the code will enable consumers to have more choice over how their data is used.

The aim of the regime is the promotion of competition within the digital market, but the Government has also indicated that the large tech platforms will soon need to be more transparent about how their services are provided and their use of customer data. In particular, the Government has emphasised that the Digital Markets Unit will be working with regulators, including the Information Commissioner's Office, to enforce the new code of conduct. From April 2021 the Digital Markets Unit could be given power over the decisions of tech giants, oblige them to take certain actions and impose financial penalties for non-compliance with the code.

The details of the code will become clearer next year. The Government intends to consult on the "form and function" of the Digital Markets Unit in early 2021.

It remains to be seen how the proposed code will interact with the UK's existing data protection regime. The Government says that "consumers will be given more choice and control over how their data is used". However the regime is driven by competition not data or consumer protection (noting that competition ultimately benefits consumers). As such, it might be too much to expect that this new regime will actually grant consumers new rights (which would not fit with the traditional nature of a code of conduct in any event). Rather, it may be that any infringement of the code, to the extent that it touched on data use, might prompt a sanction from the Digital Markets Unit that could be leveraged by consumers through existing data protection laws. If so, that would mean that tech businesses may soon face another front from which claims can brought and will be an interesting further piece of the UK's developing data litigation landscape.

New competition regime for tech giants to give consumers more choice and control over their data, and ensure businesses are fairly treated

https://www.gov.uk/government/news/new-competition-regime-for-tech-giants-to-give-consumers-more-choice-and-control-over-their-data-and-ensure-businesses-are-fairly-treated

Read more here:

Tech giants to be subject to a new code of conduct - Lexology

Report: Tech giants told Dr Wee they would review cable investments in Malaysia – SoyaCincau.com

Posted on by

Minister of Transport, Dr Wee Ka Siong, was recently criticised for his decision to revoke the cabotage exemption for foreign vessels to conduct undersea cable repairs in Malaysian waters. Last week, tech giants which include Facebook, Google, Microsoft and Malaysia Internet Exchange (MyIX) have expressed urgent concerns over the decision which will impact Malaysias internet speed and quality.

As highlighted by former Transport Minister, Anthony Loke and former Communications and Multimedia Minister, Gobind Singh in Parliament last week, the exemption was granted after requests were made from tech giants to shorten the time required to repair undersea cables. With the cabotage policy, it was reported that repairs can take up to 27 days and it has a negative impact in attracting telecommunications and internet investors.

Last Wednesday, Dr Wee had a dialogue session with Facebook, Google, Microsoft and MyIX to provide a clearer picture on the National Cabotage Policy at his office in Putrajaya. He explained that the cabotage exemption for cable repair works was revoked due to the following reasons:

The cabotage policy was introduced in Malaysia in the 1980s to protect the local shipping industry from foreign competition. With the policy in place, foreign vessels will require a Domestic Shipping License (DSL) which can be applied electronically via eDSL.

According to Dr. Wee, eDSL will reduce the time required for the process from 30 to 5 working days if there are no blockage in the application. However, the application will still require confirmation from the Malaysia Shipowners Association (MASA) that no local vessels are available to do the repair works.

The Transport Minister said it is his ministrys responsibility to ensure that vessels are allowed in areas where they are needed the most as soon as possible so that it wont impact Malaysias internet connectivity which is one of the countrys priorities.

According to a report (Tech companies say they may review cable investments in Malaysia) by The Edge Malaysia yesterday, some tech giants appear unconvinced with the new arrangements. According to the papers source who is close to the matter, one of the companies have told Dr Wee during the meeting that it would review its cable investments in Malaysia.

Another tech firm said the cabotage policy which was introduced 40 years ago was meant for passenger ships and vessels carrying goods, and are not meant for todays digital economy. It also said that the policies were implemented at a time when communications was analogue and not digital.

The Edge also sighted a position paper by Malaysia Digital Economy Corporation (MDEC) entitled Malaysia International Connectivity: Impact of Cabotage Policy on Submarine Cable Operations and Investment. The paper mentioned that Malaysias international connectivity is lagging behind regional players such as Singapore. This is due to the fact that Malaysia isnt a transit hub for transregional connectivity between the Indian and Pacific Oceans. It is also reported that one of the key factors of the situation has been highlighted by both Telekom Malaysia and Time DotCom, which operate domestic submarine cables.

The MDEC paper also mentions the lack of suitable domestic DP2 (Dynamic Positioning Class 2) cable repair vessels, which was highlighted in Parliament last week by Anthony Loke. It also added that disputes between MASA and cable operators over the issue of DSL exemption consent letter (DCL) has been the primary cause of delays.

The report also states that MASA members can block the issue of a DCL, resulting a delay in the issue of the DSL. MASA can choose not issue the DCL if its members want the cable repair job and this could lead to a mediation process if both MASA and the cable operator cannot reach a common understanding.

According to The Edge Malaysia, an industry player involved in undersea cable repairs have said that it is not viable for local companies to own vessels. Their source said After you spend millions on a submarine repair vessel, you have to pray for there to be problems and repair works with the submarine cable. It added that there are instances where submarine cables laid have not had issues for six years.

It is reported that several local companies are capable of performing submarine cable repair which include Dagang NeXchange Bhd, Optic Marine Services Sdn Bhd (OMS) and iFactors Sdn Bhd. However, the report states that only one Malaysian-flagged vessel is capable of doing repairs and it is actually a barge which requires to be towed by a tug boat. The vessel which is called Cable Orchestra is equipped with Dynamic Positioning Class 1 (DP1) capabilities but most tech giants require DP2 which is more advanced and is ideal in rougher waters.

Dynamic Positioning is a computer aided system that helps vessels to maintain a fixed position in the water by using its own set of propellers and thrusters. The industry player also said that tech companies require DP2 vessels as it is a requirement by insurance companies.

The MDEC report also states that permit delays accumulate to almost 100 days annually for submarine cable repairs in Malaysian territorial waters and exclusive Economic Zones. Cable systems under participation of TM and Time come under the South East Asia and Indian Ocean Cable Maintenance Agreement (SEAIOCMA) which include selecting the appropriate cable repair ship from contracted operators. It added that the cabotage policy restricts SEAIOCMA from choosing the best repair ship quickly and this will have a negative impact on the operations of SEAIOCMA and Malaysias aspiration to attract more submarine cable investments.

[ IMAGE SOURCE ]

Continued here:

Report: Tech giants told Dr Wee they would review cable investments in Malaysia - SoyaCincau.com

New Drug Could Improve Effectiveness of Stem Cell Therapy – Pain News Network

Posted on by

By Pat Anson, PNN Editor

Scientists have developed an experimental drug that can lure stem cells to damaged tissues and help them heal -- a discovery being touted as a major advancement in the field of regenerative medicine.

The findings, recently published in the Proceedings of the National Academy of Sciences (PNAS), could improve the effectiveness of stem cell therapy in treating spinal cord injuries, stroke, amyotrophic lateral sclerosis(ALS), Parkinsons disease and other neurodegenerative disorders. It could also expand the use of stem cells to treat conditions such as heart disease and arthritis.

The ability to instruct a stem cell where to go in the body or to a particular region of a given organ is the Holy Grail for regenerative medicine, said lead authorEvan Snyder, MD, director of theCenter for Stem Cells & Regenerative Medicineat Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA. Now, for the first time ever, we can direct a stem cell to a desired location and focus its therapeutic impact.

Over a decade ago, Snyder and his colleagues discovered that stem cells are drawn to inflammation -- a biological fire alarm that signals tissue damage has occurred. However, using inflammation as a therapeutic lure for stem cells wasnt advisable because they could further inflame diseased or damaged organs, joints and other tissue.

To get around that problem, scientists modified CXCL12 -- an inflammatory molecule that Snyders team discovered could guide stem cells to sites in need of repair to create a drug called SDV1a. The new drug works by enhancing stem cell binding, while minimizing inflammatory signals.

Since inflammation can be dangerous, we modified CXCL12 by stripping away the risky bit and maximizing the good bit, Snyder explained. Now we have a drug that draws stem cells to a region of pathology, but without creating or worsening unwanted inflammation.

To demonstrate its effectiveness, Snyders team injected SDV1a and human neural stem cells into the brains of mice with a neurodegenerative disease called Sandhoff disease. The experiment showed that the drug helped stem cells migrate and perform healing functions, which included extending lifespan, delaying symptom onset, and preserving motor function for much longer than mice that didnt receive the drug. Importantly, the stem cells also did not worsen the inflammation.

Researchers are now testing SDV1as ability to improve stem cell therapy in a mouse model of ALS, also known as Lou Gehrigs disease, which is caused by a progressive loss of motor neurons in the brain. Previous studies conducted by Snyders team found that broadening the spread of neural stem cells helps more motor neurons survive so they are hopeful that SDV1a will improve the effectiveness of neuroprotective stem cells and help slow the onset and progression of ALS.

We are optimistic that this drugs mechanism of action may potentially benefit a variety of neurodegenerative disorders, as well as non-neurological conditions such as heart disease, arthritis and even brain cancer, says Snyder. Interestingly, because CXCL12 and its receptor are implicated in the cytokine storm that characterizes severe COVID-19, some of our insights into how to selectively inhibit inflammation without suppressing other normal processes may be useful in that arena as well.

Snyders research is supported by the National Institutes of Health, U.S. Department of Defense, National Tay-Sachs & Allied Disease Foundation, Childrens Neurobiological Solutions Foundation, and the California Institute for Regenerative Medicine (CIRM).

Thanks to decades of investment in stem cell science, we are making tremendous progress in our understanding of how these cells work and how they can be harnessed to help reverse injury or disease, says Maria Millan, MD, president and CEO of CIRM. This drug could help speed the development of stem cell treatments for spinal cord injury, Alzheimers, heart disease and many other conditions for which no effective treatment exists.

Read the rest here:

New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network

Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price – Being Patient

Posted on by

Groundbreaking research in stem cells has propelled scientists understanding of neurodegenerative diseases, including Parksinsons. Could stem cell therapies one day help cure Alzheimers?

Clinical trials of stem cell therapies are now underway to repair the damaged cells of people with Parkinsons disease and age-related macular degeneration. Being Patient spoke with Jack Price, professor of developmental neurobiology at Kings College London and author of the book The Future of Brain Repair, about the potential and challenges of repairing the brain with stem cell therapy.

Being Patient: What is stem cell therapy?

Prof. Jack Price: Its the transplantation of stem cells, either directly into the brain or in a way that gives them access to the brain and influence the brain, to bring about a therapeutic effect.

Being Patient: Are there stem cells in the brain?

Prof. Jack Price: For many years, neuroscientists didnt think there were stem cells in the brain. We now know there are. We know about a population [of stem cells] thats become very important in our understanding of Alzheimers disease and in mood disorders like anxiety and depression. These are stem cells that are found in a part of the brain called the hippocampus.

But by and large, the brain doesnt have stem cells, unlike skin and other tissues in the body. The blood is the classic [example]: Theres a population of stem cells in the bone marrow that regenerates blood all the time.

Being Patient: What makes stem cells so special and why are they a focus of research?

Prof. Jack Price: The definition of stem cells is a population of cells that gives rise to other types of cells. In neural stem cells, precursor cells can make adult brain cells, nerve cells, glial cells, all the different cell types that make up the brain. If you have a disease like Alzheimers or any other neurodegenerative disease, where we know the key pathology is the loss of nerve cells, your brain doesnt normally have the ability to replace those lost brain cells. The idea was [that] if you put stem cells where the loss of brain cells has taken place, maybe those stem cells would replace the lost cells.

Being Patient: What is the potential of stem cell therapy in treating neurodegenerative diseases?

Prof. Jack Price: Theres a piece of absolutely brilliant stem cell science that was done by Shinya Yamanaka in Kyoto in 2006. He showed you could effectively take any cell through a very straightforward genetic manipulation that he discovered, [and] turn them into what we call pluripotent stem cells, which are cells that can make any cell type in the body. They also have an ability that other stem cells generally dont: They can build tissue. If you grow them in a little culture dish, they can start to make little pieces of brain called organoids or cerebroids. This was a groundbreaking technology.

In Parkinsons disease, theres enormous progress and clinical trials are underway now. We know more about the pathology of Parkinsons disease [than in Alzheimers]. The pathology of Alzheimers turns out to be quite complex, and weve had, over the years, quite a few ideas about how it worked. But [turning] those into actual therapies hasnt quite worked as we expected, and we keep having to go back and rethink whats going on in Alzheimers.

The pathology of Parkinsons disease is also difficult. Its not trivial. But at the same time, one thing is clear: a lot of the pathology is associated with the loss of a particular population of nerve cells the midbrain dopaminergic cells. We can start with these pluripotent stem cells and make them make precisely the right type of dopaminergic cell that we know is lost in Parkinsons disease.

This is built on 30 [to] 40 years of research of people trying to find exactly the right cell type to work [with] in Parkinsons disease. They had some early success and fell backwards. But this technology looks much more precise than everything anybodys ever tried before.

In age-related macular degeneration, the disease of the eye where you lose your retinal photoreceptors, there are very clever strategies now where people are using these pluripotent stem cells to make a thing called a retinal pigment epithelium. It lies behind the retina, but its what supports the photoreceptors. It turns out, thats what goes wrong in age-related macular degeneration.

Being Patient: Are there any stem cell therapy approved to treat brain disorders?

Prof. Jack Price: There are no licensed stem cell therapy for any brain disorders anywhere in the world for the simple reason [that] nobody has shown one works. There are a lot of stem cell clinics in the U.S. and somewhat fewer elsewhere who are offering cell therapies that are untested. Theyll put stem cells into you for any disorder youve got. Those cell therapies do not work.

A lot of genuine companies are trying to get these cell therapies to work in clinical trials and falling flat on their face quite often, despite their best efforts. 90% of clinical trials fail, and thats clinical trials of conventional drugs by drug companies that know what theyre doing.

What do you suppose is the chance with a stem cell therapy [that] we dont really understand how it works, [that] we dont quite know how to manufacture it properly, [and that] we dont quite know what cells we really want, of working? The chance is almost zero. These companies know that, which is why theyre not going to clinical trials.

The interview has been edited for length and clarity.

Contact Nicholas Chan at nicholas@beingpatient.com

Read the rest here:

Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient

Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai – Newswise

Posted on by

Newswise LOS ANGELES (Dec. 1, 2020) -- Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences. Chute assumed his new post Nov. 23.

The selection of Chute, following a national search, reflects the importance of his pioneering research in blood-forming stem cells called hematopoietic stem cells, which can self-renew and generate all cell types found in the blood and immune system. Over the past decade, Chute's lab has discovered several growth factors produced by the cells that line the walls of blood vessels; they play a critical role in blood-forming stem cell regeneration.

"Dr. Chute is an exceptional addition to our faculty," saidDanTheodorescu, MD, PhD, director ofCedars-Sinai Cancer. "His international reputation as a physician-scientist who has made major contributions to stem cell and hematopoietic cell biologywill greatly contribute to positioning the newly created Division of Hematology and Cell Therapy as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for the treatment of blood malignancies."

In addition to his hematopoietic stem cell research, Chute said he looks forward to expanding Cedars-Sinai's CAR T-cell research and therapy. He describes the immune-boosting therapeutic as "transformative" for patients with advanced non-Hodgkinlymphoma,childhood acute lymphoblastic leukemiaand potentially several additional blood cancers.

CAR T-cell therapy is a type of immunotherapy in which patients' own immune cells, called T cells, are collected from their blood, and then an artificial receptor chimeric antigen receptor, or CAR is added to the cells' surface. The receptor enables the modified cells to specifically eradicate cancer cells. The cells are infused back into a patient's body intravenously, where they multiply and attack tumor cells.

"CAR T therapy has become an important treatment option for so many patients with advanced cancer who had no options before," Chute said. "That's what makes CAR T therapy so exciting."

Chute joins Cedars-Sinai from the David Geffen School of Medicine at the UCLA, where he was a professor of Medicine and Radiation Oncology in the Division of Hematology/Oncology and an investigator in the Broad Stem Cell Research Center.

Chute earned his medical degree at Georgetown University. He completed his residency in internal medicine and fellowship in Hematology/Oncology at the National Naval Medical Center. He completed his research training at the National Cancer Institute and the Naval Medical Research Institute.

"I'm excited to join the Cedars-Sinai Cancer faculty because of the opportunity to collaborate with the world-class scientists and top-tier physicians at the cancer center," Chute said. "Cedars-Sinai has always been a leading medical center and is deeply committed to basic and translational research, while also growing the hematology and cellular therapy specialties. I'm eager to play a leading role in that growth."

Clickhereto read more from the Cedars-Sinai Newsroom.

Go here to see the original:

Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise

CRISPR tagging used to grow neuronal cells from stem cells – Drug Target Review

Posted on by

A new technique using CRISPR has been developed by researchers to identify programmed stem cells that mature into neuronal cells.

A team of biomedical engineers has created a new way to turn stem cells into a desired cell type using CRISPR tagging and gene regulatory networks.The study was conducted at Duke University, US.

According to the researchers, several methods already exist to programme stem cells into other cells, but often, these stem cells do not mature correctly when cultured in the lab.

The cells might seem right at first glance, but they are often missing some of the key properties you want in those cells, said Josh Black, who led the work in Charles Gersbachs lab.

Using CRISPR gene editing, the researchers created a method to identify which transcription factors master controllers of gene activity were essential to making a good neuron. They demonstrated the potential of the approach to make mature adult neurons, but say it could be applied to programme any cell type.

When Black joined Gersbachs lab, he investigated how to use these tools to turn on genes that could convert one cell type into another to create better disease models. In 2016, Black and Gersbach reported an approach to use CRISPR-based gene activators to turn on gene networks that would convert fibroblasts to neuronal cells. This study targeted gene networks that were known to be associated with neuronal specification, but did not generate cells with all of the properties needed to make effective disease models. However, the right gene networks to generate those desired cells were unknown and there are were thousands of possibilities encoded in the human genome. This led Black and Gersbach to devise a strategy to test all of the networks in a single experiment.

Starting with pluripotent stem cells, the team engineered some that fluoresced red once they became neuronal. The brighter the fluorescence, the stronger the push towards a neuronal fate. Then they made a pooled library of thousands of guide RNAs targeted to all of the genes that encode transcription factors in the human genome.

They introduced the CRISPR gene activator and guide RNA library into the stem cells so that each cell only received a single guide RNA and therefore turned on its particular corresponding transcription factor gene target. Then they sorted the cells based on how red they became and sequenced the guide RNAs in the most and least red cells, which told them which genes, when turned on, made the cells more or less neuronal.

CRISPR-based activation of gene networks implicated in human stem cells becoming neuronal cells led to the generation of cells with neuronal shapes and markers (left) and enhanced function and electrophysiological properties, including producing more action potentials more frequently (right) [credit: Gersbach Lab, Duke University].

When they profiled the gene expression from the stem cells engineered with the guide RNAs, the results suggested that the corresponding cells generated more specific and mature types of neurons. They also found genes that worked together when targeted simultaneously. Moreover, the experiment revealed factors that antagonised the neuronal commitment of the stem cells and when they used CRISPR-based repressors of those genes, they could also enhance the neuronal specification.

To know if these engineered cells recapitulated the function of more mature neurons, they turned to Professor Scott Soderling. Shataakshi Dube, a grad student in Soderlings lab, used a technique known as patch clamp electrophysiology to measure the electrical signals inside the newly formed neurons. By poking a tiny hole in the cell with a very small pipette, she looked inside the neuron and saw whether it was transmitting electrical signals known as action potentials. They found that the neurons engineered to activate a particular pair of transcription factor genes were more functionally mature, emitting more action potentials more frequently.

I was curious but sceptical on how neuronal these stem cells could become, Dube said, but it was remarkable to see how much these programmed cells looked just like normal neurons.

The process from stem cell to mature neuronal cell took seven days, dramatically shortening the timeframe compared to other methods that take weeks or months. This faster timeline has the potential to accelerate the development and testing of new therapies for neurological disorders.

The researchers say the same method for screening transcription factor genes and gene networks could be used to improve methods to make any cell type, which could be transformative for regenerative medicine and cell therapy.

The key to this work is developing methods to use the power and scalability of CRISPR-based DNA targeting to programme any function into any cell type, Gersbach said. By leveraging the gene networks already encoded in our genome, our control over cell biology is dramatically improved.

The study was conducted at Cell Reports.

See the original post here:

CRISPR tagging used to grow neuronal cells from stem cells - Drug Target Review

How Stem Cell Therapy Market Will Dominate In Coming Years? Report Covering Products, Financial Information, Developments, Swot Analysis And…

Posted on by

The Global Stem Cell Therapy Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=168110

The Global Stem Cell Therapy Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Stem Cell Therapy Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Stem Cell Therapy Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=168110

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Stem Cell Therapy Market as:Global Stem Cell Therapy Market Size & Share, by Regions

Global Stem Cell Therapy Market Size & Share, by ProductsAutologousAllogeneicStem Cell Therap

Global Stem Cell Therapy Market Size & Share, ApplicationsMusculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Key PlayersOsiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)Stem Cell Therap

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=168110

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://IndustryGrowthInsights.com

More:

How Stem Cell Therapy Market Will Dominate In Coming Years? Report Covering Products, Financial Information, Developments, Swot Analysis And...

Stem Cell Therapy Market to Witness Robust Expansion Throughout the Forecast Period 2020 2025 – The Haitian-Caribbean News Network

Posted on by

Global Stem Cell Therapy Market 2020-2025 Introduction and Scope:

This new advanced research study and presentation on the global Stem Cell Therapy Market is ready to provide you with amazing market-related details that have a significant impact on your growth. In this report, readers will find a variety of information about regional developments, including manufacturer activity, technological leaps, new government policies affecting industry operations, and country-specific growth milestones indicating a healthy growth trajectory for the global Stem Cell Therapy Market. The report also includes a variety of data that manages new M&A proposals, commercial ventures and operations, facility expansion coverage, geographic diversification, etc. that players consider to set short and long term business goals across the growth curve. Additional details regarding the competitive environment, industry pioneers, emerging companies, versatile market participants and investors were religiously emphasized.

In addition, the report has an optimal reference to the revenue-generating potential of each sector and has been evaluated to encourage the right investment. The details of geographic regions and the likelihood of favorable consumer response in each region are closely tracked to identify the growth hotspots of the global Stem Cell Therapy Market during the forecast period 2020-25.

Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

The report also provides ample information about the competitive landscape with vendor positioning and various details on the activities that remain essential growth catalysts. In addition to providing a detailed overview of the current market scenario, this section of the report also includes various details on the overall ecosystem, key trends, market catalysts, threats and challenges that significantly affect the monetization of the Stem Cell Therapy Market.

After continuing observations and research initiatives, this new research presentation on the global Stem Cell Therapy Market was recently released in order to optimally clean this global market to draw important conclusions.

The various research approaches included in this Stem Cell Therapy Market report compilation provide an internal report on the market size and growth trends, showing new trends and developments across multiple geographic tiers such as global and regional hubs as well as regional growth pockets.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Frequently Asked Questions: Global Stem Cell Therapy Market

1. In terms of product and application based segmentation, which segment is likely to remain most promising?2. Based on concurrent developments, which trends are likely to remain most dominant through the forecast span?3. Considering the pandemic crisis and other associated alterations, what could be the most relevant market projections?4. Who would continue to remain atop the growth curve in global Stem Cell Therapy Market through the forecast years?5. What are the top threats and challenges identified in the Stem Cell Therapy Market?

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Reasons to read this report:

1. It helps you understand the key product segments and their future.2. It provides accurate analysis of changing competitive dynamics and allows you to stay ahead of your competitors.3. It helps you make informed business decisions by having complete insight into the market and performing in-depth analysis of market segments.

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more here:

Stem Cell Therapy Market to Witness Robust Expansion Throughout the Forecast Period 2020 2025 - The Haitian-Caribbean News Network

Stem Cell Therapy Market Expansion Projected to Gain an Uptick During 2020-2027 – The Haitian-Caribbean News Network

Posted on by

Verified Market Research have recently published a new report on the global Stem Cell Therapy market. The study provides profound insights into updated market events and market trends. This, in turn, helps one in better comprehending the market factors, and strongly they influence the market. Also, the sections related to regions, players, dynamics, and strategies are segmented and sub-segmented to simplify the actual conditions of the industry.

The study is updated with the impacts of the coronavirus and the future analysis of the industrys trends. This is done to ensure that the resultant predictions are most accurate and genuinely calculated. The pandemic has affected all industries, and this report evaluates its impact on the global market.

Global Stem Cell Therapy Market was valued at USD 117.66 million in 2019 and is projected to reach USD 255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Stem Cell Therapy manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Dominant participants of the market analyzed based on:

The competitors are segmented into the size of their individual enterprise, buyers, products, raw material usage, consumer base, etc. Additionally, the raw material chain and the supply chain are described to make the user aware of the prevailing costs in the market. Lastly, their strategies and approaches are elucidated for better comprehension. In short, the market research report classifies the competitive spectrum of this global Stem Cell Therapy industry in elaborate detail.

Key highlights of the report:

Market revenue splits by most promising business segments by type, by application, and any other business segment if applicable within the scope of the global Stem Cell Therapy market report. The country break-up will help you determine trends and opportunities. The prominent players are examined, and their strategies analyzed.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

This Stem Cell Therapy report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Insights into the Stem Cell Therapy market scenario:

Moreover, the report studies the competitive landscape that this industry offers to new entrants. Therefore, it gives a supreme edge to the user over the other competitors in the form of reliable speculations of the market. The key developments in the industry are shown with respect to the current scenario and the approaching advancements. The market report consists of prime information, which could be an efficient read such as investment return analysis, trends analysis, investment feasibility analysis and recommendations for growth.

The data in this report presented is thorough, reliable, and the result of extensive research, both primary and secondary. Moreover, the global Stem Cell Therapy market report presents the production, and import and export forecast by type, application, and region from 2020 to 2027.

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the global Stem Cell Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Verified Market Dashboard:

VMI is BI powered Database that helps thousands of companies globally gather insights on over 20,000+ emerging and niche markets helping them make critical revenue impacting decisions. VMI assists your organization in planning for the future along with providing a holistic competitive landscape with overall market potential and in depth market share analysis broken down by Region, Country, Segments and key market leaders. VMRs database leverages its years of data gathering ability providing insights on trends and helping you with accurate future forecasts for your market research needs.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

More here:

Stem Cell Therapy Market Expansion Projected to Gain an Uptick During 2020-2027 - The Haitian-Caribbean News Network

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bios Gamma Delta T-cell product…

Posted on by

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (IN8bio or the Company), today announced an upcoming presentation that provides an update of the ongoing Phase I clinical trial of their product candidate INB-100 at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH), which will take place virtually from December 5 to 8, 2020. INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.

The poster and accompanying narrated slide presentation is titled, First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated gamma delta T-Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide and reviews the study design and provides a brief update on enrollment and patient status.

The company reported that, as of abstract submission, three female subjects with acute leukemia had been enrolled in the INB-100 Phase 1 trial, of whom two had been dosed, and that no treatment-related adverse events had been recorded. The trial is continuing to enroll and treat patients. The abstract for the presentation can be found at https://ash.confex.com/ash/2020/webprogram/Paper142876.html.

The poster and slide presentation are jointly authored by the scientific and physician investigators from IN8bio and The University of Kansas Cancer Center (KU Cancer Center), and will be presented by the studys Principal Investigator, Dr. Joseph McGuirk, Schutte-Speas Professor of Hematology-Oncology, Division Director of Hematological Malignancies and Cellular Therapeutics and Medical Director, Blood and Marrow Transplant at KU Cancer Center.

This preliminary data report from KU Cancer Center with our allogeneic product candidate, INB-100, demonstrates the absence of significant GvHD in these initial patients, said William Ho, Chief Executive Officer of IN8bio. This suggests that gamma delta T-cells delivered as an off-the-shelf allogeneic cell therapy may be well tolerated and have significant potential to treat patients with serious and life-threatening cancers.

Story continues

Dr. McGuirk, commented, Potentially curative stem cell transplants using partially matched donors -- called haploidentical transplants have greatly expanded access to stem cell transplantation. The infusion of donor-derived gamma delta T-cells from the stem cell donor, offers the hope of diminishing this risk of relapse and curing more patients.

About IN8bioIN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bios technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit http://www.IN8bio.com.

Forward Looking StatementsCertain statements herein concerning the Companys future expectations, plans and prospects, including without limitation, the Companys current expectations regarding the curative potential of its product candidates, constitute forward-looking statements. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Companys control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Companys current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Companys reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:IN8bio, Inc.Kate Rochlin, Ph.D.+1 646.933.5605info@IN8bio.com

Investor Contact:Julia Balanova+ 1 646.378.2936jbalanova@soleburytrout.com

Media Contact:Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 315 / 364Rimai@burnsmc.com / rflamm@burnsmc.com

See the original post:

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bios Gamma Delta T-cell product...

Cancer Stem Cell Therapy Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By…

Posted on by

Dataintelo publishes a detailed report on Cancer Stem Cell Therapy market providing a complete information on the current market situation and offering robust insights about the potential size, volume, and dynamics of the market during the forecast period, 2020-2026. This report offers an in-depth analysis that includes the latest information including the current COVID-19 impact on the market and future assessment of the impact on Global Cancer Stem Cell Therapy Market. The report contains XX pages, which will assist clients to make informed decision about their business investment plans and strategies for the market. As per the report by Dataintelo, the global Cancer Stem Cell Therapy market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% during the forecast period.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=117056

The Cancer Stem Cell Therapy market report also covers an overview of the segments and sub-segmentations including the product types, applications, and regions. In the light of this harsh economic condition as prompted by the COVID-19 outbreak, the report studies the dynamics of the market, changing competition landscape, and the flow of the global supply and consumption.

The report exclusively deals with key areas such as market size, scope, and growth opportunities of the Cancer Stem Cell Therapy market by analyzing the market trend and data available for the period from 2020-2026. Keeping 2019 as the base year for the research study, the report explains the key drivers as well as restraining factors, which are likely to have major impact on the development and expansion of the market during the forecast period.

The report, published by Dataintelo, is the most reliable information as the study relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies.

The report, prepared by Dataintelo, is widely known for its accuracy and factual figures as it consists of a concise graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. It uses statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Customize Report and Inquiry for the Cancer Stem Cell Therapy market Report: https://dataintelo.com/enquiry-before-buying/?reportId=117056

Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the Cancer Stem Cell Therapy market are thoroughly assessed in the report in a view to entail a broader picture of the market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Cancer Stem Cell Therapy market.

Competition Landscape:

The report covers global aspect of the market, covering

Global Cancer Stem Cell Therapy market by Types:

Autologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther

Global Cancer Stem Cell Therapy market by Applications:

HospitalClinicMedical Research InstitutionOther

Key Players for Global Cancer Stem Cell Therapy market:

AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

Avail the Discount on this report @ https://dataintelo.com/ask-for-discount/?reportId=117056

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

See the rest here:

Cancer Stem Cell Therapy Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By...

CAR T-Cell Therapy Shows Promising Early Results in Children With Neuroblastoma – Technology Networks

Posted on by

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

For this proof-of-principle study, researchers at the UCL Great Ormond Street Institute for Child Health (GOS ICH) and the UCL Cancer Institute modified the patient's own T-cells (a type of immune cell), equipping them to recognise and kill neuroblastoma tumour cells.

Twelve children with relapsed or refractory (where the disease does not respond to treatment) neuroblastoma were treated as part of the Cancer Research UK-funded phase I clinical trial.

The research, published in Science Translational Medicine, is one of the first studies to demonstrate CAR T-cells achieving rapid regression against a solid cancer (non-blood cancer). Although the beneficial effects only lasted a short while, the study provides important evidence that this specific CAR T-cell treatment could be used as a future treatment for children with solid cancers.

Neuroblastoma is a rare type of cancer that mostly affects babies and young children and develops from specialised nerve cells (neuroblasts) left behind from a baby's development in the womb.

Up to 100 children in the UK are diagnosed with neuroblastoma each year. Current treatment for children with an aggressive type of neuroblastoma includes surgical removal, chemotherapy with stem-cell transplant, radiotherapy and antibody therapy. Despite this intensive treatment long-term survival is between 50-60 per cent.

In CAR T-cell therapy, a type of immunotherapy, T-cells are engineered to contain a molecule called a chimeric antigen receptor (CAR) on their surface which can specifically recognise cancerous cells.

For this study the patients' own T-cells were modified with a CAR to target the GD2 surface protein, which is highly abundant on almost all neuroblastoma cells, but found at very low levels in healthy cells.

Researchers found that when using a sufficient dose* of the modified CAR T-cells, this treatment induced rapid reduction in tumour size in some of the patients treated. These effects were transient. Importantly, in all patients the CAR T-cells did not cause any harmful side effects in healthy tissues that express the GD2 molecule.

Lead author, Dr Karin Straathof, Research group leader at UCL GOS ICH and Consultant Paediatric Oncologist at Great Ormond Street Hospital NHS Trust said: "It's encouraging to see the anti-tumour activity induced by these modified T-cells in some of the patients on this study.

"While the anti-tumour activity seen was only transient, it provides an important proof-of-principle that CAR T-cells directed at the GD2 molecule could be used against solid cancers in children.

"New treatments are needed for high-risk neuroblastoma and with more research we hope to develop this further into a treatment that results in lasting responses and increases the number of patients that can be cured."

Senior author, Dr Martin Pule (UCL Cancer Institute) said: "Targeting of solid cancers by CAR T-cells is dependent on their infiltration and expansion within the tumour microenvironment, and thus far fewer clinical responses have been reported.

"The rapid regression in neuroblastoma cells is promising, particularly as this activity was observed in the absence of neurotoxicity which occurs with antibody-based approaches that target GD2."

Dr Pule added: "Targeting neuroblastoma with GD2 CAR T-cells appears to be a valid and safe strategy but requires further modification to promote CAR T-cell longevity."

Dr Sue Brook, medical advisor at Cancer Research UK, said: "Children who have hard to treat cancers like neuroblastoma have limited treatment options open to them, especially when the cancer returns.

"The early results for the GD2 CAR-T treatment look promising, especially due to the initial safety data. However more work is needed on making the response last longer, and we are looking forward to seeing the next steps in its development."

The research team are preparing for their next clinical study in collaboration with Autolus, a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer. This study will evaluate AUTO6NG, which builds on this approach utilising the same GD2 CAR alongside additional programming modules designed to enhance efficacy and persistence.

Reference:Straathof K, Flutter B, Wallace R, et al. Antitumor activity without on-target off-tumor toxicity of GD2chimeric antigen receptor T cells in patients with neuroblastoma.Sci. Transl. Med.2020;12(571). doi:10.1126/scitranslmed.abd6169This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View original post here:

CAR T-Cell Therapy Shows Promising Early Results in Children With Neuroblastoma - Technology Networks